Skip to main content

Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension

European Journal of Clinical Pharmacology volume 44, pages 457–462 (1993)Cite this article

Summary

To evaluate the effects of long-term treatment antihypertensive with the dihydropyridine calcium antagonist amlodipine on insulin sensitivity, plasma insulin, and lipoprotein metabolism in obese hypertensive patients.

We measured the insulin sensitivity index (SI), determined by the Minimal Model Method of Bergman, fasting plasma insulin and glucose concentrations, serum total triglyceride and lipoprotein cholesterol fractions, and blood pressure in 20 obese, non-diabetic patients with essential hypertension before and after 6 weeks of placebo and again after 6 months of amlodipine. Ten patients [mean body mass index (BMI) 30.2 kg·m−2] had been on prior treatment with a thiazide diuretic in low dosage and/or a β-adrenoceptor blocker (group A), and 10 matched patients [BMI 31.8 kg·m−2] had been previously untreated (group B). Amlodipine was started in a dose of 5 mg and was increased to 10 mg once daily in 14 patients who were hypertensive after 8 weeks on the lower dosage.

At entry (before placebo), SI was slightly but not significantly lower in group A than B [2.7 vs. 3.6×10−4 ml·μU−4·min−1]; fasting plasma insulin was 13.6 vs. 12.9 μU·ml−1. After 6 weeks on placebo, SI averaged 3.7 in group A and 4.4×10−4 μU·ml−1·min−1 in group B; fasting plasma insulin was 14.6 vs. 15.1 μU·ml−1, and glucose 5.5 vs. 5.5 mmol·l−1. After 6 months on amlodipine there were no differences in SI [group A vs. group B, 5.2 vs. 3.8×10−4 ml·μU−1·min−1], fasting insulin [13.0 vs. 12.7 μU·ml−1], glucose [5.4 vs. 5.5 mmol·l−1], serum total triglycerides, and cholesterol or lipoprotein cholesterol fractions. Compared with placebo, amlodipine significantly reduced systolic and diastolic blood pressures. Heart rate, body weight, and 24 h urinary sodium excretion were unaltered.

Long-term treatment with amlodipine does not affect insulin sensitivity, circulating insulin or glucose, or lipoprotein metabolism in obese, non-diabetic patients with essential hypertension.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

References

  1. Ferranini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S (1987) Insulin resistance in essential hypertension. New Engl J Med 1987 317: 350–357

    Google Scholar 

  2. Pyörälä K, Savolainen E, Kaukola S, Haapakoski J (1985) Plasma insulin as coronary heart disease factor: relationship to other risk factors and predictive value during 9.5-year follow-up of the Helsinki Policemen Study Population. Acta Med Scand 701 [Suppl]: 38–52

    Google Scholar 

  3. Stokes J, Kannel WB, Wolf PA, Cupples LA, D'Agostino RB (1987) The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study. Circulation 75 [Suppl V]: 65–73

    Google Scholar 

  4. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlin KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH (1990) Blood pressure, stroke and coronary heart disease. Part 2, short-term reduction in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet I: 827–838

    Google Scholar 

  5. Berne C, Pollare T, Lithell H (1991) Effects of antihypertensive treatment of insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 14 [Suppl 4]: 39–47

    Google Scholar 

  6. Ferrari P, Rosman J, Weidmann P (1991) Antihypertensive agents, serum lipoproteins and glucose metabolism. Am J Cardiol 67: 26B-35B

    Google Scholar 

  7. Weidmann P, de Courten M, Ferrari P (1993) Effect of diuretics on the plasma lipid profile. Eur Heart J (in press)

  8. Morgan KG (1987) Calcium and vascular smooth muscle tone. Am J Med 82 [Suppl 3 B]: 9–15

    Google Scholar 

  9. Wollheim CB, Sharp GWG (1981) Regulation of insulin release by calcium. Physiol Rev 61: 914–973

    Google Scholar 

  10. Draznin B, Sussman K, Kao M, Lewis D, Sherman N (1987) The existance of an optimal of cytosolic free calcium for insulin-stimulated glucose transport in rat adipocytes. J Biol Chem 262: 14385–14388

    Google Scholar 

  11. Pershadsingh HA, Shade DL, Delfert DM, McDonald JM (1987) Chelation of intracellular calcium blocks insulin action in adipocyte. Proc Natl Acad Sci USA 84: 1025–1029

    Google Scholar 

  12. Trost BN, Weidmann P (1988) Metabolic effects of calcium antagonists in humans, with emphasis on carbohydrate, lipid, potassium and uric acid homeostasis. J Cardiovasc Pharmacol 12 [Suppl 6]: S 86-S 92

    Google Scholar 

  13. Weidmann P, Boehlen LM, de Courten M (1993) Pathogenesis and treatment of hypertension associated with diabetes mellitus. Am Heart J (in press)

  14. Charles S, Ketelslegers JM, Buysschaert M, Lambert AE (1981) Hyperglycaemic effect of nifedipine. Br Med J 283: 19–20

    Google Scholar 

  15. Bhatnagar SK, Amin MAA, Al-Yusuf AR (1984) Diabetogenic effects of nifedipine. Br Med J 289: 19

    Google Scholar 

  16. Ferrari P, Giachino D, Weidmann P, Shaw S, Riesen W, Neuner N, Keller U, Heynen G (1991) Unaltered insulin sensitivity during calcium channel blockade with amlodipine. Eur J Clin Pharmacol 41: 109–113

    Google Scholar 

  17. Murdoch D, Heel RC (1991) Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 41: 478–505

    Google Scholar 

  18. Nuttall FQ, Gannon MC, Wald JL, Ahmed M (1985) Plasma glucose and insulin profiles in normal subjects ingesting diets of varying carbohydrate, fat, and protein content. J Am Coll Nutr 4: 437–450

    Google Scholar 

  19. Bergman RN, Prager R, Volund A, Olefsky JM (1987) Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 79: 790–800

    Google Scholar 

  20. Yang YJ, Youn JH, Bergman RN (1987) Modified protocols improve insulin sensitivity estimation using the minimal model. Am J Physiol 253: E595-E602

    Google Scholar 

  21. Kruse W, Weber E (1990) Dynamics of drug regimen compliance: its assessment by microprocessor-based monitoring. Eur J Clin Pharmacol 38: 561–565

    Google Scholar 

  22. Ferrari P, Allemann Y, Shaw S, Riesen W, Weidmann P (1991) Reproducibility of insulin sensitivity measured by the minimal model method. Diabetologia 34: 527–530

    Google Scholar 

  23. Ferrari P, Weidmann P, Shaw SG, Giachino D, Riesen W, Alleman Y, Heynen G (1991) Altered insulin sensitivity, hyperinsulinemia and dyslipidemia in hypertension-prone humans. Am J Med 91: 589–596

    Google Scholar 

  24. Saxenhofer H, Weidmann P, Riesen WF, Beretta-Piccoli C, Fragiacomo C, Wunderlin R, Noseda G (1990) Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemia type II. Eur J Clin Pharmacol 41: 109–113

    Google Scholar 

  25. Manual of laboratory operations. Lipid Research Clinics Program (1974) Lipid and lipoprotein analysis (publication NIH) 75–628 US Department of Health, Education of Welfare, US Government Printing Office, Washington DC

    Google Scholar 

  26. DeFronzo RA, Ferrannini E (1991) Insulin resistance a multi-faceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 173–94

    Google Scholar 

  27. Allemann Y, Horber FF, Colombo M, Ferrari P, Shaw S, Jaeger P, Weidmann P (1993) Decreased insulin sensitivity in normotensive offspring of hypertensive parents precedes gain or redistribution of body fat. Lancet I: 327–331

    Google Scholar 

  28. Istfan NW, Plaisted CS, Bistrian BR, Blackburn GL (1992) Insulin resistance versus insulin secretion in the hypertension of obesity. Hypertension 19: 385–92

    Google Scholar 

  29. Pollare T, Lithell H, Selinus I, Berne C (1989) Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double-blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J 298: 1152–1157

    Google Scholar 

  30. Pollare T, Lithell H, Mörlin C, Präntare H, Hvarfner A, Ljunghall S (1989) Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. J Hpertens 7: 551–559

    Google Scholar 

  31. Giugliano D, Torella R, Cacciapuoti F, Gentile S, Verza M, Varricchio M (1980) Impairment of insulin secretion in man by nifedipine. Eur J Clin Pharmacol 18: 395–398

    Google Scholar 

  32. Chellingsworth MC, Kendall MJ, Wright AD, Singh BM, Pasi J (1989) The effects of verapamil, diltiazem, nifedipine and propranolol on metabolic control in hypertensives with non-insulin dependent diabetes mellitus. J Hum Hypertens 3: 35–39

    Google Scholar 

  33. Kihara A (1991) Effect of the calcium antagonist nicardipine hydrochloride on glucose tolerance and insulin secretion. Am Heart J 122: 363–369

    Google Scholar 

  34. Rojdmark S, Andersson DEH (1986) Influence on verapamil on human glucose tolerance. Am J Cardiol 57: 39 D-43 D

    Google Scholar 

  35. Draznin B, Sussman KE, Eckel RH, Kao M, Yost T, Sherman NA (1988) Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinaemia. J Clin Invest 82: 1848–1852

    Google Scholar 

  36. Ferrari P, Weidmann P (1990) Insulin, insulin sensitivity and hypertension. J Hypertens 8: 491–500

    Google Scholar 

  37. Abrams JJ, Ginsberg H, Grundy SM (1982) Metabolism of cholesterol and plasma triglycerides in nonketotic diabetes mellitus. Diabetes 31: 903–910

    Google Scholar 

  38. Taskinen MR, Kuusi T, Helve E, Nikkilä EA, Yki-Järvinen H (1988) Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis 8: 168–177

    Google Scholar 

  39. Reaven GM, Banting lecture 1988 (1988) Role of insulin resistance in human disease. Diabetes 37: 1595–1607

    Google Scholar 

  40. Zavaroni I, Bonora E, Pagliara M, Dall'Aglio E, Luchetti L, Buonanno G, Bonati PA, Bergonzani M, Gnudi L, Passeri M, Reaven G (1989) Risk factors for coronary artery disease in healthy persons with hyperinsulinaemia and normal glucose tolerance. New Engl J Med 320: 702–706

    Google Scholar 

  41. Carlsen JE, Kober L, Torp-Pedersen C, Johansen P (1990) Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. Br Med J 300: 975–978

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Poliklinik, University of Berne, Berne, Switzerland

    M. de Courten, P. Ferrari, M. Schneider, L. Böhlen, S. Shaw, G. Heynen & P. Weidmann

  2. Institute for Clinical Chemistry and Haematology, State Hospital, St. Gallen, Switzerland

    W. Riesen

Authors
  1. M. de Courten
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Ferrari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Böhlen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Shaw
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W. Riesen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Heynen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P. Weidmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

de Courten, M., Ferrari, P., Schneider, M. et al. Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. Eur J Clin Pharmacol 44, 457–462 (1993). https://doi.org/10.1007/BF00315543

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00315543

Key words

  • Amlodipine
  • Hypotension
  • Insulin sensitivity
  • dihydropyridine
  • lipoprotein metabolism
  • obese hypertensive patients